IL-12 GENE THERAPY FOR TREATING IN BRCA-NEGATIVE/HOMOLOGOUS REPAIR PROFICIENT CANCERS

Title:

IL-12 GENE THERAPY FOR TREATING IN BRCA-NEGATIVE/HOMOLOGOUS REPAIR PROFICIENT CANCERS

Document Type and Number:

WIPO Patent Application WO/2024/059630

Kind Code:

A3

Abstract:

The present disclosure relates to a method for treating cancer in a subject that is BRCA-negative and homologous repair proficient (HRP), the method comprising administering to the subject a nucleic acid vector (e.g., a plasmid) comprising a polynucleotide that encodes an interleukin-12 (IL-12) formulated with a lipopolymer (e.g., a nanoparticle). In some aspects, the method further comprises administering to the subject an anticancer agent (e.g., a chemotherapeutic agent), an antibody or antigen-binding fragment thereof that specifically binds a vascular endothelial growth factor (VEGF) (anti-VEGF antibody), an immune checkpoint inhibitor, or any combination thereof.

More Like This:

WO/1991/001004	HYBRID MOLECULES
JPH09508625	[Title of Invention] Combined administration of interleukin-3 mutant and colony stimulating factor
WO/2024/015724	POLYCISTRONIC miRNA CONSTRUCTS FOR IMMUNE CHECKPOINT INHIBITION

Inventors:

ANWER KHURSHEED (US)
BORYS NICHOLAS (US)

Application Number:

PCT/US2023/074064

Publication Date:

April 25, 2024

Filing Date:

September 13, 2023

Export Citation:

Click for automatic bibliography generation Help

Assignee:

IMUNON INC (US)

International Classes:

C07K14/54; A61K38/00; A61K39/00; C12N15/87

Attorney, Agent or Firm:

NANNENGA-COMBS, Bonnie W. et al. (US)

Download PDF:

View/Download PDF PDF Help

Previous Patent: IL-12 GENE THERAPY AND IMMUNE CHECKPOINT INHIBITOR COMBINATION FOR TREATING CANCER

Next Patent: R-TRIHEXYPHENIDYL FOR TREATMENT OF MOVEMENT DISORDERS